Details:
Through this agreement, OliX will use its GalNAc-asiRNA platform technology to discover lead compounds and secure development candidates for targets in cardiovascular, metabolic, and other diseases associated with the liver.
Lead Product(s): siRNA Therapeutics
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Discovery Product Type: Large molecule
Partner/Sponsor/Collaborator: Hansoh Pharma
Deal Size: $456.5 million Upfront Cash: $6.5 million
Deal Type: Collaboration October 19, 2021